louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05572645: Pyrotinib Plus Trastuzumab Versus Pertuzumab Plus Trastuzumab
Official title: Pyrotinib Plus Trastuzumab Versus Pertuzumab Plus Trastuzumab in HER2-Positive Metastatic Breast Cancer: a Multicenter, Retrospective Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Breast Cancer
Keywords: Pyrotinib
Trastuzumab
Pertuzumab
Lead sponsor: Fudan University
Sponsor class: OTHER
First posted: 2022-10-10
Enrollment: 333
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients diagnosed with breast cancer (according to ICD-10) with confirmed metastasis, regardless of being de novo diagnosed or progressed from a non-metastatic stage

Brief summary: Pyrotinib Plus Trastuzumab Versus Pertuzumab Plus Trastuzumab

Detailed description: This is a retrospective study aiming to explore the efficacy and safety of Pyrotinib Plus Trastuzumab Versus Pertuzumab Plus Trastuzumab in patients with HER2-positive metastatic breast cancer.

Eligibility criteria: Inclusion Criteria:

* HER2+ MBC patients scored +3 by immunohistochemical (IHC) analysis or scored +2 and the result of fluorescence in situ hybridization was positive.
* Patients received Pyrotinib(320-400 mg, po, qd) plus Trastuzumab(8 mg/kg q3w, and then 6 mg/kg q3w) or Pertuzumab(840mg q3w, and then 420 mg q3w) plus Trastuzumab(8 mg/kg q3w, and then 6 mg/kg q3w) for at least one cycle, starting from Jan 2018 to Sep 2022.
* Patients had complete medical records. All data were retrospectively collected from medical records of individual institutions.

Exclusion Criteria:

* Incomplete medical history

Primary outcomes:
measure: PFS
timeFrame: 6 weeks
Secondary outcomes:
measure: Adverse Events
timeFrame: 6 weeks
Other outcomes:
Locations:
city: Shanghai
country: China
facility: Fudan University Shanghai Cancer Center
state: Shanghai
Study officials:
References:
Clinical trial NCT06981845: Sirolimus With corTicOsteroid TheraPy for Rapid rEcurrences of Coronary Unexplained In-stent Restenosis
Official title: Sirolimus With corTicOsteroid TheraPy for Rapid rEcurrences of Coronary Unexplained In-stent Restenosis (STOP-RECUR) Study
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: In-stent Restenosis Lesion
Coronary Artery Disease (CAD) (E.G., Angina, Myocardial Infarction, and Atherosclerotic Heart Disease (ASHD))
Lead sponsor: China National Center for Cardiovascular Diseases
Sponsor class: OTHER_GOV
Collaborators: name: Chinese Academy of Medical Sciences, Fuwai Hospital
name: The First Hospital of Jilin University
First posted: 2025-05-21
Enrollment: 52
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study aims to evaluate, through a multicenter, prospective, double-blind, randomized, placebo-controlled clinical trial, whether immunosuppressive therapy improves target lesion-related cardiovascular outcomes compared to placebo treatment in patients with Rapid rEcurrence of Coronary Unexplained in-stent Restenosis (RECUR).


Eligibility criteria: Inclusion Criteria:

1. Age ≥ 18 years old
2. Able to understand the trial design and sign an informed consent form
3. Patients meeting the RECUR definition
4. Satisfactory results from revascularization within the past two weeks
5. Receiving standard secondary prevention medication for coronary heart disease with treatment targets achieved

Exclusion Criteria:

Pregnant women, individuals known to be allergic to the study drug, those currently participating in other interventional clinical trials, or participants deemed unsuitable for this study based on the investigator's judgment.

Primary outcomes:
measure: Target vessel failure (TVF)
timeFrame: During the 1 year follow-up
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT01796145: Fibroscan Study in HCC
Official title: A Study to Evaluate the Impact of Liver Stiffness on Treatment Outcome of Hepatocellular Carcinoma
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: NA
Conditions: Confirmed Diagnosis of Hepatocellular Carcinoma
Patients Who Are Scheduled to Undergo Transarterial Chemobolization, Systemic Therapy Surgery
Child's A to C Cirrhosis
Lead sponsor: Chinese University of Hong Kong
Sponsor class: OTHER
First posted: 2013-02-21
Enrollment: 207
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: In patients with HCC undergoing therapy 1. We aim to determine the prognostic significance of liver stiffness in patients with HCC 2. We aim to determine the rate and severity of complications of treatment and its association with liver stiffness in patients with HCC


Eligibility criteria: Inclusion Criteria:

* Clinical diagnosis of HCC
* Patients who are scheduled to undergo therapy, either TACE systemic therapy or surgery

  1. For TACE cohort, patients undergoing first cycle TACE are eligible.
  2. For systemic therapy cohort, patients undergoing first-line systemic therapy are eligible.
  3. For surgery cohort, patient undergoing surgery are eligible.
* Prior surgery or loco-ablative therapy (e.g. Radiofrequency ablation, microwave, percutaneous ethanol injection) is allowed
* Child's A to Child's C liver function

Exclusion Criteria:

* ECOG performance status \> 2
* Poorly controlled ascites

Primary outcomes:
measure: Overall survival
timeFrame: 3 years
Secondary outcomes:
measure: Rate and grade of treatment complications
timeFrame: 2 years
measure: Liver stiffness (kPa)
timeFrame: 2 years
Other outcomes:
Locations:
city: Hong Kong
country: Hong Kong
facility: Department of Clinical Oncology, Prince of Wales Hospital
Study officials:
affiliation: Chinese University of Hong Kong
name: Stephen Lam Chan, FHKCP
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04379245: COVID-19 Infection in Patients Infected With HIV and/or on PrEP
Official title: Study of the Attack Rate of COVID-19 Infection in Patients Infected With HIV and/or on Pre-exposure Prophylaxis (PrEP) and Possible Impact of Treatment With an HIV Protease Inhibitor
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: HIV
Pre-exposure Prophylaxis
Lead sponsor: Hospices Civils de Lyon
Sponsor class: OTHER
First posted: 2020-05-07
Enrollment: 4200
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Two populations will be studied:

* HIV patients in Hospices Civils de Lyon
* on PrEP patients in Hospices Civils de Lyon

Brief summary: The SARS-CoV-2 epidemic was declared as a global pandemic by the WHO on March 12, 2020. France is affected with approximately 120,000 biologically confirmed cases, as of April 30, 2020, a figure probably very underestimated. Its distribution in different populations, in particular immunocompromised, has not yet been measured. The in vitro efficacy of lopinavir coupled with ritonavir, an HIV protease inhibitor, on SARS-CoV, responsible for SARS has been discussed and this therapeutic combination is currently being evaluated in patients infected with COVID-19. The possible protective role of treatment with Lopinavir / ritonavir or another HIV protease inhibitor has not been studied.

In addition, patients receiving HIV pre-exposure prophylaxis (PrEP) share certain epidemiological and behavioral characteristics with HIV-infected patients.

The objective was to carry out an epidemiological study aimed at determining the attack rate of COVID-19 infection in patients infected with HIV and or on PrEP and to analyze this attack rate according to the characteristics of these 2 populations and in particular the existence or not of an antiretroviral treatment comprising Lopinavir / Ritonavir or another inhibitor of the HIV protease.

Cross-referencing of Virology Laboratory data (positive or negative screening) and clinical-biological data can be easily carried out using a unique identification number in the 2 software programs and will allow an almost exhaustive epidemiological analysis in 2 well identified populations.


Eligibility criteria: Inclusion Criteria:

* HIV patients in Hospices Civils de Lyon
* on-PrEP patients in Hospices Civils de Lyon

Exclusion Criteria:

-

Primary outcomes:
measure: Covid attack rate
timeFrame: During hospitalisation for Covid symptoms: one week (max 2 weeks) after symptoms initiation
Secondary outcomes:
Other outcomes:
Locations:
city: Lyon
country: France
facility: Croix-Rousse Hospital, Hospices Civils de Lyon
Study officials:
References:
Clinical trial NCT03003845: S1P1 Receptor Subtype (S1PR1) Axis in Patients With Interstitial Cystitis (IC) Pain
Official title: Activation of the Sphingosine-1-phosphate (S1P) to S1P1 Receptor Subtype (S1PR1) Axis in Patients With Interstitial Cystitis (IC) Pain : Identification of Potential Relevant Biomarkers
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Interstitial Cystitis
Lead sponsor: St. Louis University
Sponsor class: OTHER
First posted: 2016-12-28
Enrollment: 21
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Women are included. The onset of interstitial cystitis usually occurs between 30 and 70 years of age, with a median age of 43.

.

Brief summary: For each patient in the study, blood, and pain scores will be collected to look for markers for pain, at the start of treatment and 6 months after surgery of treatment.

Detailed description: The study is investigator-initiated, prospective, study. There will be no change in care.

Patients who have had a diagnosis of IC made by cystoscopy and hydrodistension and still have pain will be recruited for this study.

Patients will have blood samples taken at the visit they sign the consent form and 6 months later.

The study staff will call and remind the patient of their 6 month visit.

Eligibility criteria: Inclusion Criteria:

* 18-70 years of age
* Patients must be able to provide written informed consent.
* Diagnosis of Interstitial Cystitis documented by provider

Exclusion Criteria:

* age \<18 or \>70 years of age
* pregnant

Primary outcomes:
measure: Change From Baseline in Pain Scores on the Visual Analog Scale at 6 months
timeFrame: 3 months
Secondary outcomes:
Other outcomes:
Locations:
city: Saint Louis
country: United States
facility: Saint Louis University Department of Obstetrics, Gynecology, and Women's Health
state: Missouri
Study officials:
affiliation: St. Louis University
name: Eugen C Campian, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01692145: A Parallel Group Phase II Study of KCT-0809 in Patients With Dry Eye Syndromes
Official title: A Randomized, Double Blind, Placebo Controlled, Parallel Group Phase II Study of KCT-0809 in Patients With Dry Eye Syndromes
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Dry Eye Syndromes
Keywords: Dry eye syndromes
Corneal diseases
Conjunctival diseases
Lead sponsor: Kissei Pharmaceutical Co., Ltd.
Sponsor class: INDUSTRY
First posted: 2012-09-25
Sex: ALL
Minimum age (years): 20
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate the efficacy and safety of KCT-0809 compared to placebo in patients with dry eye syndromes.


Eligibility criteria: Inclusion Criteria:

* Corneal and conjunctival damage
* Insufficiency of lacrimal secretion
* Ocular symptom

Exclusion Criteria:

* Severe ophthalmic disorder
* Punctual plugs or surgery for occlusion of the lacrimal puncta

Primary outcomes:
measure: Score of the Corneal conjunctival staining
Secondary outcomes:
Other outcomes:
Locations:
city: Tokyo and Other Japanese City
country: Japan
facility: Japan
Study officials:
References:
Clinical trial NCT06182345: Spray Skin Treats for Pediatric Burns
Official title: Spray Skin Treats in the Treatment of Pediatric Burns
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Pediatric Burn
Keywords: Pediatric burn
Spray skin
skin graft
Lead sponsor: First Affiliated Hospital, Sun Yat-Sen University
Sponsor class: OTHER
First posted: 2023-12-26
Enrollment: 100
Sex: ALL
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Children with burns from various reasons

Brief summary: The treatment of burns in children remains a global challenge. At present, the clinical treatment plan is still waiting for further improvement. This study intends to retrospectively analyze the experience of treating children burn in recent years and promote sharing and application.

Detailed description: The treatment of burns in children remains a global challenge. Children's burn wounds have many characteristics that are different from those of adults, such as easy deepening of the wound, uncooperation in dressing change, poor resistance and so on. At present, there are new dressing applications a nd surgery in clinical treatment, etc., but how to treat children to achieve better therapeutic effects still needs to be explored. This study intends to retrospectively analyze the experience of treating children burn in recent years and promote sharing and application.

Eligibility criteria: Inclusion Criteria:

* burn for any reasons
* Children

Exclusion Criteria:

* Combined with mental illness
* Congenital immune disease
* Severe cardiopulmonary failure，etc

Primary outcomes:
measure: take rate
timeFrame: postoperative day 4 weeks
Secondary outcomes:
measure: complication rate
timeFrame: through study completion, an average of 6 months
Other outcomes:
Locations:
city: Guangzhou
country: China
facility: Department of Burn Surgery, The First Affiliated Hospital of Sun Yat-sen University
state: Guangdong
Study officials:
affiliation: First Affiliated Hospital, Sun Yat-Sen University
name: Jiayuan Zhu
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05381545: Laser Puncture and Program of Lifestyle Modification in Lupus Females
Official title: Laser Puncture and Program of Lifestyle Modification in Lupus Females: Lipid Profile Response
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Systemic Lupus Erythematosus
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2022-05-19
Enrollment: 64
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Serum lipid profile was significantly dysregulated in female systemic lupus erythematosus (SLE) patients

Detailed description: the research will recruit 64 female systemic lupus erythematosus (SLE) obese patients to divide them to two study groups equally. the study groups will receive, for 12 weeks, energy expenditure program (Pilates exercise, managed 5 times per week, combined with low calorie diet for).One group only will receive an additional laser puncture (with 3-time per-week design). The following points will be directly contacted by laser, for two minutes: GB34\&28, ST25\&36\&40, SP6, and CV4\&9\&12.

Eligibility criteria: Inclusion Criteria:

* obese female participants
* Lupus females

Exclusion Criteria:

* pregnant lupus female
* lactating lupus females
* neurologic or articular disorders
* another autoimmune conditions

Primary outcomes:
measure: triglycerides
timeFrame: 12 weeks
Secondary outcomes:
measure: high density lipoprotein
timeFrame: 12 weeks
measure: cholesterol
timeFrame: 12 weeks
measure: low density lipoprotein
timeFrame: 12 weeks
Other outcomes:
Locations:
city: Giza
country: Egypt
facility: Faculty of Physical Therapy Cairo University
state: Dokki
Study officials:
affiliation: Cairo University
name: Ali Ismail, lecturer
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01153945: Association Between Cancer Cells and Normal Versus (Vs.) Low Levels of Thyroid Hormones in the Serum
Official title: Association Between Cancer Cells and Normal Vs. Low Levels of Thyroid Hormones in the Serum
Study type: OBSERVATIONAL
Overall status: WITHDRAWN
Conditions: Thyroid Cancer
Keywords: Hypothyroid and non hypothyroid
Lead sponsor: Meir Medical Center
Sponsor class: OTHER
First posted: 2010-06-30
Enrollment: 0
Sex: ALL
Minimum age (years): 20
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Thyroid cancer patients before/after radioactive iodine total body scan or treatment admitted to the Endocrinology Institute, Meir Medical Center

Brief summary: Much experimental data has suggested that thyroid hormones (T3 and T4) may modulate neoplastic cells and that T3/T4 deprivation may remove this stimulus. It is now well established that T3/T4 affects cell division/angiogenesis through binding to integrin avb3, commonly over-expressed on many cancer cells. In the experimental settings, mimicking hypothyroidism in the cells is a difficult task. Currently, the use of charcoal stripped serum is used. Using this method, the serum is stripped not only from T3 and T4, as intended, but also from central and important cytokines and growth factor. This leads to a reduced rate of cancer cell proliferation and thus, does not reflect the natural environment in which cancer cells residue under hypothyroid conditions.

The investigators aim to characterize and establish the effects of serum from hypothyroid patients on the proliferation/viability of a variety of cancer cell models.


Eligibility criteria: Inclusion Criteria:

* Hypothyroid state

Exclusion Criteria:

* Non hypothyroid state

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Kfar-Saba
country: Israel
facility: Meir Medical Center
Study officials:
affiliation: Meir Medical Center
name: Dan Nabriski, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00723645: Rate and Predictors of Relapse in the Treatment of Hepatitis C (Study P05181)
Official title: Rate and Predictors of Relapse in the Treatment of Hepatitis C in Real-life Clinical Practice in Spanish Hospitals (FAST-4)
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Hepatitis C, Chronic
Lead sponsor: Merck Sharp & Dohme LLC
Sponsor class: INDUSTRY
First posted: 2008-07-29
Enrollment: 279
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Adult subjects with chronic hepatitis C who were treated for the first time with pegylated interferon alfa-2b plus ribavirin and achieved end-of-treatment response.

Brief summary: This is an observational, multicenter, nationwide study where information will be collected on the follow-up of participants with chronic hepatitis C virus (HCV) who have a viral response at the end of treatment with pegylated interferon alfa-2b (PEG IFN alfa-2b) plus ribavirin (RBV) administered according to the directions on the products' labeling. No administration of treatment is planned as a result of study enrollment.


Eligibility criteria: Inclusion Criteria:

* Participants with chronic hepatitis C virus (HCV)\[any genotype\] who received pegylated interferon alfa-2b plus ribavirin as first treatment for hepatitis C.
* Negative HCV RNA at the end of treatment (24 or 48 weeks according to the product labeling as appropriate), measured by the assay used at each institution. Only institutions using an assay with a limit of detection of 50 IU/mL or less will be eligible.

Exclusion Criteria:

* Women of childbearing potential (i.e., premenopausal women and women who are less than 6 months postmenopausal) who will not use an appropriate contraceptive method during the course of the clinical study. Appropriate contraceptives include double barrier methods (eg, diaphragm or condom plus spermicide), intrauterine device, oral, injectable or subcutaneous hormonal contraceptive, or surgically sterilized partner.
* Completed treatment with pegylated interferon alfa-2b plus ribavirin more than 4 weeks before study entry.
* Positive HCV RNA at the end of treatment (24 or 48 weeks according to the product labeling as appropriate).
* Participants treated for a period shorter than the enrollment period.
* Co-infection with Human Immumodeficiency Virus (HIV).
* Co-infected with Hepatitis B Virus (HBV).

Primary outcomes:
measure: Percentage of Participants With Relapse At 24 Weeks After the End Of Treatment (EOT)
timeFrame: From enrollment (≤4 weeks after end of treatment) to Week 24 post-treatment
Secondary outcomes:
measure: Percentage of Participants Who Relapsed After EOT at Week 72 (Late Relapser)
timeFrame: From 24 weeks post-treatment to 72 weeks post-treatment
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT06877845: Postural Correctors & Activity Trackers in Total Knee Replacement Rehab
Official title: Effects of Postural Corrector and Activity Tracker for Enhanced Post-operative Rehabilitation of Total Knee Replacement
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Total Knee Replacement
Keywords: Pain
Knee Function
Post-operative Rehabilitation
Lead sponsor: Riphah International University
Sponsor class: OTHER
First posted: 2025-03-14
Enrollment: 20
Sex: ALL
Minimum age (years): 40
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: * To assess the impact of postural corrector on post-operative knee function and activity
* To evaluate the role of activity tracker in monitoring and enhancing post-operative rehabilitation
* To assess the effects of postural corrector and activity tracker on pain management during rehabilitation

Detailed description: Knee osteoarthritis is a major public health threat. Chronic pain and incapacity related to knee degenerative arthritis (OA) is current among the older population in several developed countries and also the condition is marked by many pathological characteristics, like joint house narrowing and also the formation of osteophytes, Despite the pressing want for effective hindrance and treatment methods, there's a scarcity of comprehensive demographic knowledge on the general prevalence of the un wellness and also the specific subgroups affected

Eligibility criteria: Inclusion Criteria:

* Participants who fall in this category will be included in the study.

  * Commercially available devices
  * Post-operative total knee replacement
  * Males and females
  * Age 40 to 60 years

Exclusion Criteria:

* Participants who fall in this category will be excluded from the study.

  * Non wearable devices
  * Patient had been through surgery more than 1 month
  * Patients with any other disorder or disease

Primary outcomes:
measure: OKS (Oxford Knee Score) to assess Function and Pain in Knee
timeFrame: 12 Weeks
measure: UCLA Activity Scale for assessing the Physical Activity Level of patients undergoing Knee & Hip Arthoplasty
timeFrame: 12 Weeks
measure: EQ-5D-5L (EuroQol 5-DIMENSION 5-Level) to measure the health-related quality of life (HRQoL)
timeFrame: 12 Weeks
measure: NPRS (NUMERIC PAIN RATING SCALE) for Pain
timeFrame: 12 Weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Mānsehra
country: Pakistan
facility: Helping Hand Institute of Rehabilitation Sciences (HHIRS)
state: KPK
Study officials:
affiliation: Riphah International University
name: Ayesha Sadiq, MSPT (OMPT)
role: PRINCIPAL_INVESTIGATOR
References: